Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Volociximab

Next Previous
X
Search
Drug Profile

Volociximab

Alternative Names: Anti-α5β1 integrin antibody; Eos 200-4; M 200

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PDL BioPharma
  • Developer Abbott Biotherapeutics Corp; Biogen Idec; IVERIC bio; National Cancer Institute (USA); PDL BioPharma
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Integrin alpha 5 beta 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Age-related macular degeneration; Intestinal cancer; Non-small cell lung cancer; Peritoneal cancer
  • Discontinued Malignant melanoma; Pancreatic cancer; Renal cell carcinoma

Most Recent Events

  • 16 Apr 2019 Ophthotech Corporation is now called IVERIC bio
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Age-related-macular-degeneration in USA (Intravitreous, Injection)
  • 24 Jan 2013 Discontinued - Phase-II for Ovarian cancer (monotherapy, second-line) in USA (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top